Skip to main content
Download PDF

A noval prognostic signature of the N7-methylguanosine (m7G)-related miRNA in lung adenocarcinoma

BMC Pulmonary Medicine volume 23, Article number: 14 (2023) Cite this article

Abstract

Background

Lung adenocarcinoma (LUAD) is characterized by high morbidity and mortality rates and poor prognosis. N7-methylguanosine play an increasingly vital role in lung adenocarcinoma. However, the prognostic value of N7-methylguanosine related-miRNAs in lung adenocarcinoma remains unclear.

Methods

In the study, the mRNA and miRNA expression profiles and corresponding clinical informations were downloaded from the public database. The prognostic signature was built using least absolute shrinkage and selection operator Cox analysis. The Kaplan–Meier method was used to compare survival outcomes between the high- and low-risk groups. Signatures for the development of lung adenocarcinoma were tested using univariate and multivariate Cox regression models. Single-sample gene set enrichment analysis was used to determine the immune cell infiltration score. First, we predicted METTL1 and WDR4 chemosensitivities based on a public pharmacogenomics database. The area under the receiver operating characteristic curve showed that the performance of signature in 1-,3-, and 5-year survival predictions were 0.68, 0.65, and 0.683, respectively.

Results

We established a novel prognostic signature consisting of 9 N7-Methylguanosine related miRNAs using least absolute shrinkage and selection operator Cox analysis. Patients in the high-risk group had shorter survival times than those in the low-risk group did. The calibration curves at 1, 3, and 5-year also illustrate the high predictive power of the structure. Signature was corrected using the Toumor stage. The expression levels of METTL1 and WDR4 significantly correlated with the sensitivity of cancer cells to antitumor drugs.

Conclusions

A novel signature constructed using 9 N7-methylguanosine related-miRNAs can be used for prognostic prediction.

Peer Review reports

Introduction

Human health is primarily threatened by lung adenocarcinoma (LUAD), which causes high morbidity and mortality [1]. Lung cancer is the second most common and fatal cancer worldwide, according to data released in 2021 [2]. According to statistics, the main trend in the incidence of lung cancer in recent years is that lung adenocarcinoma (LUAD) has increased and lung squamous carcinoma (LUSA) has decreased annually [2]. At the present time, the mechanisms of lung cancer occurrence and development are not entirely understood. Thus, further understanding of the mechanisms that contribute to the development and prevention of lung cancer is urgently required.

N7-methylguanosine (m7G) is the most ubiquitous RNA cap modification [3] and also functions in transcription, mRNA splicing, and translation [4, 5]. Recent studies have shown that m7G plays an increasingly vital role in human diseases, especially cancer [6]. It has recently been found that methyltransferase-like 1(METTL1)-mediated m7G methylation affects the stability of the stem-loop structure by disrupting the RNA G-quadruplexs (G4s), thereby promoting its process from pri- to pre-miRNA, ultimately leading to miRNA maturation [7]. Mature miRNAs can function as oncogenes or tumor suppressors by binding to downstream target genes [8]. Moreover, whether these m7G-related miRNAs affect lung cancer prognosis remains unknown.

In the present study, we identified m7G-related mRNAs. We used the public prediction platform TargetScan (TargetScan Release 7.2, URL: http://www.targetscan.org/) to search for m7G-related miRNAs. M7G-related miRNAs were systematically analyzed using bioinformatic methods, and important miRNAs were selected to construct a prognostic model for LUAD.

Materials and methods

Data collection

Raw data were downloaded from a public database website (https://portal.gdc.cancer.gov/projects/tcga). It contains mRNA sequencing information of 497 cases of LUAD and 54 cases of normal lung tissue, miRNA sequencing information of 521 cases of LUAD and 46 cases of normal lung tissue, as well as the corresponding clinical data. Two m7G-related mRNAs, METTL1 and WD-repeat domain 4 (WDR4), were obtained from related studies [9].

Construction and validation of a M7G-related miRNA signature

TargetScan software is dedicated to the analysis of mammalian miRNA target genes. Using this software, m7G-related mRNAs targeting miRNAs (m7G-related miRNAs) were predicted. The expression matrix of m7G-related miRNAs was extracted using R (version 3.4.4). The m7G-related miRNA expression matrix was normalized using R software "limma" package. The “edgR” package performed differential analysis of the normalized m7G-related miRNAs expression matrix between LUAD and normal tissues, and obtains m7G-related differentially expressed miRNAs (DEmiRs). Taking |logFC(fold change)|> 1 and adj. p < 0.05 as the screening criteria, the p value was adjusted using the Benjamini-Hochberg(BH) method. The correlation of m7G-related DEmiRs with patient overall survival (OS) was assessed through univariate Cox proportional hazards regression analysis using the survival coxph function of the R package. Lasso-penalized Cox regression was used to build an m7G-related prognostic miRNA signature. The risk score was calculated as follows: Risk score = esum(each miRNA’s expression * corresponding coefficient). Based on the median risk score, the patients were divided into high- and low-risk groups. The R software of the Rtsne package was used to perform principal component analysis (PCA) and t-SNE analysis of m7G-related DEmiRs based on the constructed model. A time-dependent receiver operator characteristic (ROC) curve analysis (1-, 3-, and 5-year) was conducted to assess the prediction accuracy of the signature using the survival and time ROC R package. The area under the curve (AUC) was used to measure the survival predicting the efficacy of the prognostic model. Calibration curve is an important indicator for evaluating models. Through the Hosmer–Lemeshow test, the p value was divided into 3 equal parts, and the difference between the predicted value and the actual value of each equal fraction was found. The above steps were completed through the “pec” package of the R software. The Nomogram transformed complex regression equations into visual graphs, making the results of predictive models more readable and convenient for patient evaluation. We used the Bootstrap self-sampling method and the modeling data to verify the predictive effect. This analysis was performed through the R languages “survival” and “rms” again.

The infiltration levels of 16 types of immune cells were quantified by single-sample gene set enrichment analysis (ssGSEA) using the gsva package in R software. At the same time, the ESTIMATE algorithm was used to evaluate the tumor microenvironment, including immune, stromal, and ESTIMATE scores. Spearman’s correlation method was used to evaluate the correlation between the risk score and the other variables. Pearson’s correlation was applied to detect correlations between variables of interest. Statistical significance was set at p < 0.05. The R software packages ggpubr and ggcorrplot were used to perform correlation analysis.

Predictive chemosensitivity drug analysis

The United States National Cancer Institute (NCI) offers a panel of 60 human tumor cell lines (NCI-60 panel, https://dtp.cancer.gov/discovery_development/nci-60/) [10]. The R software package, pRRophetic, was used to predict METTL1 and WDR4 chemosensitivity based on a public pharmacogenomics database, Genomics of Drug Sensitivity in Cancer. The drug responses for 263 FDA-approved or clinical trial drugs were used in the correlation analysis.

Statistical analysis

M7G-related DEmiRs were compared between LUAD and normal tissues using Wilcoxon test. The two-sided chi square test for independent proportions will be used for proportion comparisons. Mann–Whitney test was used to compare ssGSEA scores of high-risk and low-risk immune cells, and p-value was adjusted using the BH method. The Kaplan–Meier method was used to evaluate the significant difference in OS between the high- and low-risk groups. Univariate and multivariate Cox regression analyses were used to identify independent risk factors for LUAD. Spearman’s correlation method was used to evaluate the correlation between the risk score and the other variables. Pearson or Spearman correlation analysis was applied to detect correlations between variables of interest. Statistical significance was set at p < 0.05.

Results

The flow diagram of the study is shown in Fig. 1. The raw data consisted of mRNA (497 cases of LUAD and 54 cases of normal lung tissue) and miRNA(521 cases of LUAD and 46 cases of normal lung tissue) sequencing information of LUAD from The Cancer Genome Atlas (TCGA) database.

Fig. 1
figure 1

Technical roadmap of the study

Full size image

Identification of prognostic m7G-related differential miRNAs

Using TargetScan software, 792 miRNAs (m7G-related miRNAs) targeted by METTL1 and WDR4 were selected (Additional file 3: Table S1). Differential analysis revealed 88 m7G-related DEmiRs (63 upregulated and 25 downregulated) in normal and LUAD tissues (Fig. 2A). In univariate survival analysis, 16 m7G-related DEmiRs were associated with OS (Fig. 2B).

Fig. 2
figure 2

Model establishment. A Differential analysis, volcano plot represented the 88 m7G-related differentially expressed miRNAs between normal and lung adenocarcinoma (LUAD) tissues, of which the red was upregulated and the green was downregulated; B Univariate Cox proportional hazards regression analysis of overall survival of the correlation of m7G-related DEmiRs; C Partial likelihood deviance of overall survival for the LASSO coefficient profiles.; D Multivariate Cox proportional hazards regression analysis of overall survival of the correlation of m7G-related DEmiRs

Full size image

Establishment of a prognostic model

LASSO-Cox regression was performed to select the most effective variables from the 16 m7G-related DEmiRs to construct multivariate prediction models (Fig. 2C). When ʎ = 0.0246, nine m7G-related DEmiRs were selected (Fig. 2D). The prediction model signature was constructed as follows: Risk score = (0.095 × expression level of miRNA-3191-5p) + (4.001296e−04 × expression level of hsa-miR-495-3p) + (0.107 × expression level of hsa-miR-450a-1-3p) + (0.085 × expression level of hsa-miR-196b-3p) + (3.171833e−03 × expression level of hsa-miR-221-5p) + (4.475949e−04 × expression level ofhsa-miR-31-5p) + (− 0.156 × expression level of hsa-miR-3667-5p) +  6.897294e −07 × expression level of hsa-miR-192-5p) + (0.044 × expression level of hsa-miR-6858-5p). All patients were divided into two groups based on the median risk score: high-risk (n = 245) and low-risk (n = 245) (Fig. 3A, B). As expected, higher survival rates were observed in the low risk group than in the high-risk group. The results of PCA and t-SNE analysis showed that the high- and low-risk groups were well-distributed in two different directions (Fig. 3C, D). In survival analysis based on the risk score, the low-risk group showed better survival (p < 0.001, Fig. 3E). The area under the ROC receiver operating characteristic curve indicates that the performance of signature in 1-,3-, and 5-year survival predictions were 0.68, 0.65, and 0.683, respectively (Fig. 3F).

Fig. 3
figure 3

Prognostic analysis of the 9-miRNAS. A The distribution and median values of the risk scores in different groups.; B Distribution of risk scores for the high- and low-risk groups; C Principal component analysis separated samples between high- and low-risk; D t-SNE analysis of samples between high- and low-risk; E Kaplan–Meier curves for overall survival of patients in the high- and low-score groups; F The area under time-dependent receiver operator characteristic curves for overall survival

Full size image

Independent prognostic value of the signature

To determine whether the risk score is an independent prognostic factor for LUAD, univariate and multivariate Cox regression analyses were performed on the clinical characteristics and risk score. Univariate Cox regression analysis showed that the risk score was significantly associated with OS (p < 0.001, HR = 2.267, 95% CI 1.619–3.174, Fig. 4A). Multivariate regression analysis showed that risk score was an independent predictor of OS (p < 0.001, HR = 2.035, 95% CI 1.447–2.862, Fig. 4B). We generated a nomogram plot of the clinicopathological features and risk scores (Fig. 4C). The nomogram plot suggested that patients with lower risk scores and younger and lower stages had better survival rates. The calibration curves at 1, 3, and 5-year also illustrate the high predictive power of the structure (Fig. 4D).

Fig. 4
figure 4

Signature validation. A Univariate Cox proportional hazards regression analysis of overall survival of the correlation of clinical characteristics and risk score; B Multivariate Cox proportional hazards regression analysis of overall survival of the correlation of clinical characteristics and risk score C Overall survival nomogram for LUAD patients; D Calibration plots for the nomogram

Full size image

Survival analysis of the nine m7G-related DEmiRs used to construct the prognostic model revealed that hsa-miR-873-3p (p < 0.001), hsa-miR-450a-1-3p (p = 0.002), hsa-miR-196b-3p (p = 0.029), hsa-miR-31-5p (p = 0.004), and hsa-miR-192-5p (p = 0.030) had significant prognostic significance for LUAD, and all showed better survival times at low expression (Fig. 5A–E). Moreover, these nine m7G-related DEmiRs were significantly highly expressed in LUAD (p < 0.05, Additional file 1: Fig. S1).

Fig. 5
figure 5

Kaplan–Meier survival analysis of miRNAs for the overall survival in lung adenocarcinoma (LUAD) patients, red reprented high expression, and green represented low expression. A hsa-miR-873-3p; B hsa-miR-450a-1-3p; C hsa-miR-196b-3p; D hsa-miR-31-5p; E hsa-miR-192-5p

Full size image

The risk score was only correlated with tumor stage in terms of clinical characteristics. The risk score was higher in the high stage (stages III-IV) than in the low stage (stages I–II) (p = 0.0031, Additional file 2: Fig. S2).

Immune correlates analysis

Using the ssGSEA method, the infiltration of 16 immune cells was analyzed using the ssGSEA score as the standard. Between the high- and low-risk groups, activated dendritic cells (aDCs), mast cells, and tumor-infiltrating lymphocytes (TIL) showed significant differences (adj. p < 0.05) (Fig. 6A). The correlation analysis results of 16 immune cells showed that Treg and T helper cells showed a strong positive correlation (R = 0.91). Treg and NK cells showed a strong negative correlation (R = − 0.88) (Fig. 6B). The results from the ESTIMATE algorithm showed that the immune score, stromal score, and ESTIMATE of the tumor microenvironment were statistically different between the high- and low-risk groups (Fig. 6C). With the exception of TIL, METTL1 and WDR4 showed a certain degree of correlation with the remaining immune infiltrating cells. WDR4 showed a strong negative correlation with CD8+ T cells, mast cells, and T follicular helper (Tfh) (R = − 0.8, p < 0.05). METTL1 showed a strong positive correlation with natural killer (NK) cells (R = 0.8, p < 0.05) and a strong negative correlation with T helper cells and regulatory T [Treg] cells (R = − 0.8, p < 0.05) (Fig. 6D). Only hsa-miR-221-5p was positively correlated with Dendritic cells (DCs) and Treg Among the miRNAs used to construct the prognostic model (R = 0.2, p < 0.05; Fig. 6E).

Fig. 6
figure 6

Immune cell infiltration. A Immune status of immune cells between high- and risk-score; B Correlation analysis of immune cells; C Immune status of tumor microenvironment between high- and risk-score; D Correlation analysis of METTL1 and WDR4 exprerssion wirh immune cells; E Correlation analysis of m7G related miRNA exprerssion wirh immune cells

Full size image

METTL1 and WDR4 expression and cancer cell sensitivity to chemotherapy

We used the NCI-60 cell line to investigate the sensitivity of METTL1 and WDR4 to chemotherapy. The results showed that the expression of these two genes was positively correlated with chemotherapy drugs (p < 0.01, Fig. 7). For example, increasing the expression of WDR4 significantly improved the sensitivity to cladribine, 6 − THIOGUANINE, Thiotepa, hydroxyurea, and other drugs. We also found that all drugs that responded to METTL1 responded to WDR4 and were positively correlated.

Fig. 7
figure 7

Scatter plot of expression of METTL1 and WDR4 with chemosensitivity

Full size image

Discussion

Lung cancer is a malignant tumor of the bronchial epithelium, and its morbidity and mortality are extremely high worldwide [11]. Owing to the high morbidity and mortality of lung cancer, the discipline of integrating and analyzing the data of lung cancer patients through public databases and bioinformatics methods has gradually emerged in recent years. In the past few decades, the application of high-throughput technology in molecular biology has not only changed the research methods of biology and biomedicine but also laid the foundation for the development of bioinformatics. miRNAs are involved in various biological processes of tumor evolution, including tumor cell proliferation, apoptosis, cell cycle regulation, adhesion, and angiogenesis induction [12]. Therefore, the abnormal expression of miRNAs is closely related to the occurrence and development of tumors. When its expression is upregulated or downregulated, it can be used as a tumor-promoting or tumor-suppressing factor to target and regulate the gene expression of downstream signaling pathways [13], and plays an important role in various malignant tumors, including lung cancer [14].

Although some studies have shown the regulatory role of m7G methylation in the occurrence and development of lung cancer [14], there are no reports on the use of m7G-related miRNAs to construct a prognostic model. We found 88 m7G-related DEmiRs (11.1%) among 792 m7G-related miRNAs between LUAD and normal tissues. Univariate regression analysis revealed that the 16 m7G-related DEmiRs were associated with OS. LASSO regression was further selected, and nine m7G-related DEmiR (hsa-miR-873-3p, hsa-miR-495-3p, hsa-miR-450a-1-3p, hsa-miR-196b-3p, hsa-miR-221 -5p, hsa-miR-31-5p, hsa-miR-3667-5p, hsa-miR-192-5p, and hsa-miR-6858-5p) prognostic models were constructed. The m7G-related miRNA signature predicted the AUC of 1-, 3-, and 5-year survival of LUAD to be 0.68, 0.65, and 0.684, respectively. Patients were divided into high- and low-risk groups based on the median risk score and the expression levels of the nine m7G-related DEmiRs. We found that the patients in the high-risk group had lower immune cell infiltration and shorter survival times. Moreover, the risk score can be used as an independent predictor of LUAD prognosis. The expression of the nine m7G-related miRNAs built into the model was higher in LUAD tissues than in normal tissues and showed statistical differences. In particular, the expression of hsa-miR-196b-3p in normal lung tissue was extremely low. The results of differential analysis of immune cell infiltration between the high- and low-risk groups showed that the level of immune cell infiltration in the high-risk group was generally lower than that in the low-risk group. Immune cells closely related to LUAD showed statistically significant differences (DCs and Tregs).

The M7G-related miRNAs that constitute the prognostic model can be roughly divided into three categories. The first type has a promoting effect on tumors (hsa-miR-196b-3p, hsa-miR-221-5p, and hsa-miR-31-5p). MiR-196b-3p, as the degraded product from the 3 prime of its precursor miR-196b, significantly increased expression in recurrent epithelial ovarian cancer [15]. JEONG et al. [16] found that hsa-miR-196b-3p promotes the progression of prostate cancer. MiR-196b enhanced NSCLC cell migration and invasion by downregulating GATA6 [17]. A study by Liao et al. [18] showed that hsa-miR-221-5p is highly expressed in NSCLC and that this high expression promotes the malignant phenotype of NSCLC cells, which is consistent with our findings. Hsa-miR-31-5p is widely accepted as an oncogenic miRNA that is involved in the proliferation, migration, invasion, and chemosensitivity of various tumor cancer cells [19,20,21,22]. Hsa-miR-31-5p is ectopically upregulated in various malignancies [23]. Studies have shown that miR-31-5p expression is associated with the Warburg effect in lung tumorigenesis [24, 25]. Yu F found that hsa-miR-31-5p significantly accelerated the metastasis of LUAD cells in vitro and in vivo [26]. In this study, it was found that hsa-miR-31-5p was significantly upregulated in HExo and bound to protein 2 by targeting a specific AT-Rich sequence (SATB2), and activation of the MEK/ERK pathway promotes tumor progression [26]. The second type has an inhibitory effect on the proliferation and invasion of tumor cells (hsa-miR-873-3p, hsa-miR-495-3p, hsa-miR-192-5p, and hsa-miR-3667-5p). Some studies have proposed that hsa-miR-873-3p mediates NFATC2 and GSK3B (Wnt pathway) to regulate LUAD cell proliferation and invasion [27]. Wnt signaling is an oncogenic driver in lung, breast, liver, and ovarian cancers [28]. In NSCLC, hsa-miR-495 binds to the HOXC93-UTR region and inhibits its expression, suggesting that it plays a tumor suppressor role in the MIR-495/HOXC9 pathway [29]. In our study, the low-expression hsa-miR-495-3p group had better survival time and was highly expressed in LUAD, suggesting that it is a negative regulator. Hsa-miR-192-5p is involved in a variety of human diseases, especially various cancers, including lung, liver, cervical, and breast cancers [30, 31]. However, they play different roles in different tumors. Similar to HCC, prostate cancer [32] promotes tumor erosion. Hsa-miR-192-5p inhibits NSCLC cell proliferation through the Wnt/β-catenin signaling pathway [33]. Few studies have focused on the functions of hsa-miR-3677 in human cells. Studies have shown that hsa-miR-3677 is inversely associated with overall survival in HCC patients [34]. Targeting SphK1 via hsa-miR-3677 has also been shown to inhibit the progression of human osteosarcoma cells [35]. However, there are few reports of related research on lung cancer.

The last category is almost unreported. These miRNAs were proposed for the first time to play different roles in LUAD cells (hsa-miR-450a-1-3p and hsa-miR-6858-5p). Hsa-miR-450a-1-3p is widely expressed in various tissues, but little is known about its biological functions. Only studies have shown that its expression is different in endometrial carcinosarcoma and prostate cancer [36]. Some studies have found that the target gene regulated by hsa-miR-450a-1-3p is Bub1 [37]. Spindle assembly checkpoint (SAC) lesions caused by Bub1 dysregulation play an important role in tumorigenesis [37]. Hsa-miR-6858-5p is a key regulator of melatonin (MEL) suppresses the malignant properties of GBM [38]. Hsa-miR-450a-1-3p, hsa-miR-6858-5p regulate METTL1 of m7G-related genes in lung cancer. METTL1 can function in LUAD cells through the AKT/mTORC1 pathway, and upregulation of METTL1 occurs early in LUAD development [39]. We speculated that hsa-miR-450a-1-3p and hsa-miR-6858-5p may also act in the early stages of LUAD through the AKT/mTORC1 pathway. However,the specific functions need to be studied further. However, our study found that hsa-miR-450a-1-3p was highly expressed in LUAD, whereas low expression was associated with better survival time. Hsa-miR-450a-1-3p positively regulates the proliferation of LUAD cells.

The risk scores were more strongly associated with a higher clinical stage. This result further suggests that higher risk scores and later clinical stages are associated with poorer survival rates. Immune-infiltrating aDCs, mast cells, and TIL showed higher immune scores and differences in the low-risk group. This could also explain the better survival of the patients in the low-risk group. Analysis of the tumor microenvironment and risk score also supported the conclusion that patients in the low-risk group had longer survival times. METTL1 was positively correlated with aDCs, mast cells, and TIL, while WDR4 was the opposite. These three types of immune cells were strongly and positively correlated with each other. This indicates that the immunoregulatory effect of METTL1 is greater than that of WDR4 in the tumor microenvironment. In a previous analysis, METTL1 was significantly elevated in the early stages of LUAD, promoting tumors. In some studies, it was found that the expression of METTL1 did not change significantly from LUAD stage I–stage IV and was in a state of high expression [40]. M7G methylation mediated by METTL1 promotes tumor proliferation in the early stages of LUAD [39]. However, with the development of tumors, the promotion effect is inhibited owing to the intervention of a certain mechanism, but the immune mechanism of METTL1 is stimulated. Dynamic modification of RNA enables cells to respond rapidly to changes in the external environment and adapt to the changing microenvironment. The METTL family can function through a variety of mechanisms to regulate the maturation, differentiation, and function of immune infiltrating cells, thereby affecting the occurrence of immune responses and stability of the immune system [41, 42]. METTL3 plays an important role in the normal differentiation of Tn cells, maintenance of Treg inhibitory function, activation of aDC, polarization of macrophages, and expression of inflammatory factors [42]. In the colorectum, METTL14 expression levels affect the infiltration of CD8 + T cells [43].

Using the NCI-60 database, we found that with the increased expression of METTL1 and WDR4, the sensitivity of some FDA-approved chemotherapeutics was also enhanced. Cisplatin and gemcitabine are commonly used as second-line drugs for the treatment of non-small cell lung cancer. However, drugs such as cladribine and thiotepa have also been used to treat other tumors. These drugs may provide new insights into the treatment of LUAD.

However, there are still some limitations in this paper. We provided the prognostic relationship of nine N7-Methylguanosine related miRNAs with LUAD patients only based on the analysis of public databases, and we only theoretically analyzed the effect of expressions of METTL1 and WDR4 on chemotherapeutic agents in LUAD patients. This study lacks external database and experiments in vivo or in vitro to validate the above findings. All of these things need to be improved later.

Conclusion

Overall, our study established a novel prognostic signature consisting of 9 m7G-related miRNAs. Multidimensional analysis revealed that singularity was an independent prognostic factor in patients with LUAD. However, there are still theoretical and experimental deficiencies in the regulation of m7G methylation during the development of LUAD, which is worthy of further exploration.

Availability of data and materials

The datasets used and/or analysed during the current study available from the corresponding author on reasonable request.

References

  1. Xie H, Zhang JF, Li Q. Identification and analysis of genes associated with lung adenocarcinoma by integrated bioinformatics methods. Ann Hum Genet. 2021;85(3–4):125–37. https://doi.org/10.1111/ahg.12418.

    Article  CAS  Google Scholar 

  2. Yoo S, Sinha A, Yang D, Altorki NK, Tandon R, Wang W, Chavez D, Lee E, Patel AS, Sato T, Kong R, Ding B, Schadt EE, Watanabe H, Massion PP, Borczuk AC, Zhu J, Powell CA. Integrative network analysis of early-stage lung adenocarcinoma identifies aurora kinase inhibition as interceptor of invasion and progression. Nat Commun. 2022;13(1):1592. https://doi.org/10.1038/s41467-022-29230-7.

    Article  CAS  Google Scholar 

  3. Cowling VH. Regulation of mRNA cap methylation. Biochem J. 2009;425(2):295–302. https://doi.org/10.1042/bj20091352.

    Article  Google Scholar 

  4. Pei Y, Shuman S. Interactions between fission yeast mRNA capping enzymes and elongation factor Spt5. J Biol Chem. 2002;277(22):19639–48. https://doi.org/10.1074/jbc.M200015200.

    Article  CAS  Google Scholar 

  5. Muthukrishnan S, Both GW, Furuichi Y, Shatkin AJ. 5’-Terminal 7-methylguanosine in eukaryotic mRNA is required for translation. Nature. 1975;255(5503):33–7. https://doi.org/10.1038/255033a0.

    Article  CAS  Google Scholar 

  6. Lin S, Liu Q, Jiang YZ, Gregory RI. Nucleotide resolution profiling of m(7)G tRNA modification by TRAC-Seq. Nat Protoc. 2019;14(11):3220–42. https://doi.org/10.1038/s41596-019-0226-7.

    Article  CAS  Google Scholar 

  7. Deng Y, Zhou Z, Ji W, Lin S, Wang M. METTL1-mediated m(7)G methylation maintains pluripotency in human stem cells and limits mesoderm differentiation and vascular development. Stem Cell Res Ther. 2020;11(1):306. https://doi.org/10.1186/s13287-020-01814-4.

    Article  CAS  Google Scholar 

  8. Yang Z, Sun Q, Guo J, Wang S, Song G, Liu W, Liu M, Tang H. GRSF1-mediated MIR-G-1 promotes malignant behavior and nuclear autophagy by directly upregulating TMED5 and LMNB1 in cervical cancer cells. Autophagy. 2019;15(4):668–85. https://doi.org/10.1080/15548627.2018.1539590.

    Article  CAS  Google Scholar 

  9. Dai Z, Liu H, Liao J, Huang C, Ren X, Zhu W, Zhu S, Peng B, Li S, Lai J, Liang L, Xu L, Peng S, Lin S, Kuang M. N(7)-methylguanosine tRNA modification enhances oncogenic mRNA translation and promotes intrahepatic cholangiocarcinoma progression. Mol Cell. 2021;81(16):3339-3355.e3338. https://doi.org/10.1016/j.molcel.2021.07.003.

    Article  CAS  Google Scholar 

  10. Lee JK, Havaleshko DM, Cho H, Weinstein JN, Kaldjian EP, Karpovich J, Grimshaw A, Theodorescu D. A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proc Natl Acad Sci USA. 2007;104(32):13086–91. https://doi.org/10.1073/pnas.0610292104.

    Article  CAS  Google Scholar 

  11. Bai R, Yuan C, Sun W, Zhang J, Luo Y, Gao Y, Li Y, Gong Y, Xie C. NEK2 plays an active role in tumorigenesis and tumor microenvironment in non-small cell lung cancer. Int J Biol Sci. 2021;17(8):1995–2008. https://doi.org/10.7150/ijbs.59019.

    Article  CAS  Google Scholar 

  12. Wang Q, He Y, Kan W, Li F, Ji X, Wu X, Wang X, Zhang Y, Chen J. microRNA-32-5p targets KLF2 to promote gastric cancer by activating PI3K/AKT signaling pathway. Am J Transl Res. 2019;11(8):4895–908.

    CAS  Google Scholar 

  13. Blosse A, Levy M, Robe C, Staedel C, Copie-Bergman C, Lehours P. Deregulation of miRNA in helicobacter pylori-induced gastric MALT lymphoma: from mice to human. J Clin Med. 2019. https://doi.org/10.3390/jcm8060845.

    Article  Google Scholar 

  14. Yerukala Sathipati S, Ho SY. Identifying the miRNA signature associated with survival time in patients with lung adenocarcinoma using miRNA expression profiles. Sci Rep. 2017;7(1):7507. https://doi.org/10.1038/s41598-017-07739-y.

    Article  CAS  Google Scholar 

  15. Chong GO, Jeon HS, Han HS, Son JW, Lee YH, Hong DG, Lee YS, Cho YL. Differential MicroRNA expression profiles in primary and recurrent epithelial ovarian cancer. Anticancer Res. 2015;35(5):2611–7.

    CAS  Google Scholar 

  16. Jeong JH, Park SJ, Dickinson SI, Luo JL. A constitutive intrinsic inflammatory signaling circuit composed of miR-196b, Meis2, PPP3CC, and p65 drives prostate cancer castration resistance. Mol Cell. 2017;65(1):154–67. https://doi.org/10.1016/j.molcel.2016.11.034.

    Article  CAS  Google Scholar 

  17. Li H, Feng C, Shi S. miR-196b promotes lung cancer cell migration and invasion through the targeting of GATA6. Oncol Lett. 2018;16(1):247–52. https://doi.org/10.3892/ol.2018.8671.

    Article  CAS  Google Scholar 

  18. Liao L, Wang J, Feng S, Lan Z, Lyu X, Wu M, Yang X. The expression of miR-221 and miR-222 in non-small cell lung cancer and their significances. Cancer Res Clin. 2016;28(9):590–4. https://doi.org/10.3760/cma.j.issn.1006-9801.2016.09.004.

    Article  Google Scholar 

  19. Jung M, Schaefer A, Steiner I, Kempkensteffen C, Stephan C, Erbersdobler A, Jung K. Robust microRNA stability in degraded RNA preparations from human tissue and cell samples. Clin Chem. 2010;56(6):998–1006. https://doi.org/10.1373/clinchem.2009.141580.

    Article  CAS  Google Scholar 

  20. Creighton CJ, Fountain MD, Yu Z, Nagaraja AK, Zhu H, Khan M, Olokpa E, Zariff A, Gunaratne PH, Matzuk MM, Anderson ML. Molecular profiling uncovers a p53-associated role for microRNA-31 in inhibiting the proliferation of serous ovarian carcinomas and other cancers. Can Res. 2010;70(5):1906–15. https://doi.org/10.1158/0008-5472.Can-09-3875.

    Article  CAS  Google Scholar 

  21. Manceau G, Imbeaud S, Thiébaut R, Liébaert F, Fontaine K, Rousseau F, Génin B, Le Corre D, Didelot A, Vincent M, Bachet JB, Chibaudel B, Bouché O, Landi B, Bibeau F, Leroy K, Penault-Llorca F, Van Laethem JL, Demetter P, Tejpar S, Rossi S, Mosakhani N, Osterlund P, Ristamäki R, Sarhadi V, Knuutila S, Boige V, André T, Laurent-Puig P. Hsa-miR-31-3p expression is linked to progression-free survival in patients with KRAS wild-type metastatic colorectal cancer treated with anti-EGFR therapy. Clin Cancer Res: Off J Am Assoc Cancer Res. 2014;20(12):3338–47. https://doi.org/10.1158/1078-0432.Ccr-13-2750.

    Article  CAS  Google Scholar 

  22. Sun D, Yu F, Ma Y, Zhao R, Chen X, Zhu J, Zhang CY, Chen J, Zhang J. MicroRNA-31 activates the RAS pathway and functions as an oncogenic microRNA in human colorectal cancer by repressing RAS p21 GTPase activating protein 1 (RASA1). J Biol Chem. 2013;288(13):9508–18. https://doi.org/10.1074/jbc.M112.367763.

    Article  CAS  Google Scholar 

  23. Alder H, Taccioli C, Chen H, Jiang Y, Smalley KJ, Fadda P, Ozer HG, Huebner K, Farber JL, Croce CM, Fong LY. Dysregulation of miR-31 and miR-21 induced by zinc deficiency promotes esophageal cancer. Carcinogenesis. 2012;33(9):1736–44. https://doi.org/10.1093/carcin/bgs204.

    Article  CAS  Google Scholar 

  24. Edmonds MD, Boyd KL, Moyo T, Mitra R, Duszynski R, Arrate MP, Chen X, Zhao Z, Blackwell TS, Andl T, Eischen CM. MicroRNA-31 initiates lung tumorigenesis and promotes mutant KRAS-driven lung cancer. J Clin Investig. 2016;126(1):349–64. https://doi.org/10.1172/jci82720.

    Article  Google Scholar 

  25. Zhu B, Cao X, Zhang W, Pan G, Yi Q, Zhong W, Yan D. MicroRNA-31-5p enhances the Warburg effect via targeting FIH. FASEB J: Off Publ Fed Am Soc Exp Biol. 2019;33(1):545–56. https://doi.org/10.1096/fj.201800803R.

    Article  CAS  Google Scholar 

  26. Yu F, Liang M, Huang Y, Wu W, Zheng B, Chen C. Hypoxic tumor-derived exosomal miR-31-5p promotes lung adenocarcinoma metastasis by negatively regulating SATB2-reversed EMT and activating MEK/ERK signaling. J Exp Clin Cancer Res: CR. 2021;40(1):179. https://doi.org/10.1186/s13046-021-01979-7.

    Article  CAS  Google Scholar 

  27. Lou W, Ding B, Fu P. Pseudogene-derived lncrnas and their miRNA sponging mechanism in human cancer. Front Cell Dev Biol. 2020. https://doi.org/10.3389/fcell.2020.00085.

    Article  Google Scholar 

  28. Kothari V, Goodwin JF, Zhao SG, Drake JM, Yin Y, Chang SL, Evans JR, Wilder-Romans K, Gabbara K, Dylgjeri E, Chou J, Sun G, Tomlins SA, Mehra R, Hege K, Filvaroff EH, Schaeffer EM, Karnes RJ, Quigley DA, Rathkopf DE, He HH, Speers C, Spratt DE, Gilbert LA, Ashworth A, Chinnaiyan AM, Raj GV, Knudsen KE, Feng FY. DNA-dependent protein kinase drives prostate cancer progression through transcriptional regulation of the Wnt signaling pathway. Clin Cancer Res: Off J Am Assoc Cancer Res. 2019;25(18):5608–22. https://doi.org/10.1158/1078-0432.Ccr-18-2387.

    Article  CAS  Google Scholar 

  29. Bi R, Wei W, Lu Y, Hu F, Yang X, Zhong Y, Meng L, Wang M, Jiang L, Xie X. High hsa_circ_0020123 expression indicates poor progression to non-small cell lung cancer by regulating the miR-495/HOXC9 axis. Aging. 2020;12(17):17343–52. https://doi.org/10.18632/aging.103722.

    Article  CAS  Google Scholar 

  30. Mokhlesi A, Talkhabi M. Comprehensive transcriptomic analysis identifies novel regulators of lung adenocarcinoma. J Cell Commun Sign. 2020;14(4):453–65. https://doi.org/10.1007/s12079-020-00565-4.

    Article  Google Scholar 

  31. Xu J, Zou J, Wu L, Lu W. Transcriptome analysis uncovers the diagnostic value of miR-192-5p/HNF1A-AS1/VIL1 panel in cervical adenocarcinoma. Sci Rep. 2020;10(1):16584. https://doi.org/10.1038/s41598-020-73523-0.

    Article  CAS  Google Scholar 

  32. Zou X, Wei J, Huang Z, Zhou X, Lu Z, Zhu W, Miao Y. Identification of a six-miRNA panel in serum benefiting pancreatic cancer diagnosis. Cancer Med. 2019;8(6):2810–22. https://doi.org/10.1002/cam4.2145.

    Article  CAS  Google Scholar 

  33. Kumar S, Sharawat SK, Ali A, Gaur V, Malik PS, Kumar S, Mohan A, Guleria R. Identification of differentially expressed circulating serum microRNA for the diagnosis and prognosis of Indian non-small cell lung cancer patients. Curr Probl Cancer. 2020;44(4):100540. https://doi.org/10.1016/j.currproblcancer.2020.100540.

    Article  Google Scholar 

  34. Mao HX, Chen BW, Wang J, Ma CY, Gan YC, Qiu KJ. miR-3677-5p promotes the proliferation, migration and invasion of hepatocellular carcinoma cells and is associated with prognosis. Exp Ther Med. 2021;22(1):780. https://doi.org/10.3892/etm.2021.10212.

    Article  CAS  Google Scholar 

  35. Wang Y, Ao X, Wang Y, Ding D, Lu T, Wang J. Differential expression profiles of circular RNA in gastric cancer tissue. J Precis Med. 2019;34(1):6–10. https://doi.org/10.13362/j.jpmed.201901002.

    Article  Google Scholar 

  36. Castilla M, Moreno-Bueno G, Romero-Pérez L, Van De Vijver K, Biscuola M, López-García M, Prat J, Matías-Guiu X, Cano A, Oliva E, Palacios J. Micro-RNA signature of the epithelial-mesenchymal transition in endometrial carcinosarcoma. J Pathol. 2011;223(1):72–80. https://doi.org/10.1002/path.2802.

    Article  CAS  Google Scholar 

  37. Luo M, Weng Y, Tang J, Hu M, Liu Q, Jiang F, Yang D, Liu C, Zhan X, Song P, Bai H, Li B, Shi Q. MicroRNA-450a-3p represses cell proliferation and regulates embryo development by regulating Bub1 expression in mouse. PLoS ONE. 2012;7(10):e47914. https://doi.org/10.1371/journal.pone.0047914.

    Article  CAS  Google Scholar 

  38. Wang C, Zhao Z, Qi Q, Wang J, Kong Y, Feng Z, Chen A, Li W, Zhang Q, Wang J, Huang B, Li X. miR-6858 plays a key role in the process of melatonin inhibition of the malignant biological behavior of glioma. J Clin Neurosci: Off J Neurosurg Soc Australasia. 2021;87:137–46. https://doi.org/10.1016/j.jocn.2021.02.015.

    Article  CAS  Google Scholar 

  39. Uddin MB, Wang Z, Yang C. Dysregulations of functional RNA modifications in cancer. Cancer Stemness Cancer Ther Ther. 2020;10(7):3164–89. https://doi.org/10.7150/thno.41687.

    Article  CAS  Google Scholar 

  40. Lin S, Liu Q, Lelyveld VS, Choe J, Szostak JW, Gregory RI. Mettl1/Wdr4-mediated m(7)G tRNA methylome is required for normal mRNA translation and embryonic stem cell self-renewal and differentiation. Mol Cell. 2018;71(2):244-255.e245. https://doi.org/10.1016/j.molcel.2018.06.001.

    Article  CAS  Google Scholar 

  41. Pan T. Modifications and functional genomics of human transfer RNA. Cell Res. 2018;28(4):395–404. https://doi.org/10.1038/s41422-018-0013-y.

    Article  CAS  Google Scholar 

  42. Liberman N, O’Brown ZK, Earl AS, Boulias K, Gerashchenko MV, Wang SY, Fritsche C, Fady PE, Dong A, Gladyshev VN, Greer EL. N6-adenosine methylation of ribosomal RNA affects lipid oxidation and stress resistance. Sci Adv. 2020;6(17):4370. https://doi.org/10.1126/sciadv.aaz4370.

    Article  CAS  Google Scholar 

  43. Yang X, Zhang S, He C, Xue P, Zhang L, He Z, Zang L, Feng B, Sun J, Zheng M. METTL14 suppresses proliferation and metastasis of colorectal cancer by down-regulating oncogenic long non-coding RNA XIST. Mol Cancer. 2020;19(1):46. https://doi.org/10.1186/s12943-020-1146-4.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

Thanks for the supports from Key Laboratory of Tumor Precision Medicine, Hunan colleges and Universities Project (No. 2019-379), Scientific Research Fund of Hunan Provincial (19JJ80073), and Scientific Research Fund of Chenzhou (lcyl2021098).

Funding

This study was supported by: 1. Key Laboratory of Tumor Precision Medicine, Hunan colleges and Universities Project (No. 2019-379). 2. Scientific Research Fund of Hunan Provincial (19JJ80073). 3. Scientific Research Fund of Chenzhou (lcyl2021098).

Author information

Author notes

  1. Han-ping Duan, Jian-hui Yan and Lin Nie are contributed equally to this work

Authors and Affiliations

  1. Department of Nuclear Medicine, Affiliated Hospital (Clinical College) of Xiangnan University, Chenzhou, 423000, Hunan Province, People’s Republic of China

    Han-ping Duan

  2. Department of General Medicine, Affiliated Hospital (Clinical College) of Xiangnan University, Chenzhou, 423000, Hunan Province, People’s Republic of China

    Jian-hui Yan

  3. Department of Radiology, Affiliated Hospital (Clinical College) of Xiangnan University, Chenzhou, 423000, Hunan Province, People’s Republic of China

    Lin Nie

  4. Department of Thoracic Surgery, Affiliated Hospital (Clinical College) of Xiangnan University, Chenzhou, 423000, Hunan Province, People’s Republic of China

    Ye Wang

  5. Department of Radiation Oncology, Affiliated Hospital (Clinical College) of Xiangnan University, No. 25, Renmin West Road, Chenzhou, 423000, Hunan Province, People’s Republic of China

    Hui Xie

  6. Key Laboratory of Medical Imaging and Artifical Intelligence of Hunan Province, 423000, Chenzhou, People’s Republic of China

    Hui Xie

Authors
  1. Han-ping Duan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jian-hui Yan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lin Nie
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ye Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hui Xie
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

HD, JY, LN, and HX designed the study, searched, analyzed and interpreted the literature and are the major contributors in writing the manuscript. YW collect the case data and XH revised the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Hui Xie.

Ethics declarations

Ethics approval and consent to participate

Not applicable, because the patients involved in the public database have obtained ethical approval, users can download relevant data for free for research and publish relevant articles, and our study is based on open-source data, and the Affiliated Hospital (Clinical College) of Xiangnan University do not require research using publicly available data to be submitted for review to their ethics committee, so there are no ethical issues and other conflicts of interest.

Consent for publication

Not applicable.

Competing interests

All authors declare they have no conflict of interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1. Supplementary Figure 1

. M7G related miRNA exprerssion between normal and tumor tissus.

Additional file 2. Supplementary Figure 2

. The relationship between risk score and clinical features.

Additional file 3. Supplementary Table 1

. 792 miRNAs targeted by METTL1 and WDR4.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Duan, Hp., Yan, Jh., Nie, L. et al. A noval prognostic signature of the N7-methylguanosine (m7G)-related miRNA in lung adenocarcinoma. BMC Pulm Med 23, 14 (2023). https://doi.org/10.1186/s12890-022-02290-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12890-022-02290-7

Keywords

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us